Tokyo, Nov. 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063676) titled 'Japanese Patient Preferences for Bladder Sparing Therapies in Non Muscle Invasive Bladder Cancer NMIBC A Discrete Choice Experiment' on Nov. 20.

Study Type: Observational

Primary Sponsor: Institute - Ferring Pharmaceuticals Co., Ltd.

Condition: Condition - Non-Muscle-Invasive Bladder Cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To quantify patient preferences for the efficacy, safety, and administration attributes of bladder-sparing therapies for NMIBC. Basic objectives2 - Others

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not a...